
1. Malar J. 2016 Jan 15;15:28. doi: 10.1186/s12936-015-1016-5.

Functional analysis of monoclonal antibodies against the Plasmodium falciparum
PfEMP1-VarO adhesin.

Guillotte M(1)(2), Nato F(3), Juillerat A(4)(5), Hessel A(6)(7), Marchand F(8),
Lewit-Bentley A(9)(10), Bentley GA(11)(12), Vigan-Womas I(13)(14)(15),
Mercereau-Puijalon O(16)(17).

Author information: 
(1)Institut Pasteur, Unité d'Immunologie Moléculaire des Parasites, 25-28 rue du 
Dr ROUX, 75015, Paris, France. micheline.guillotte-blisnick@pasteur.fr.
(2)URA CNRS 2581, 25-28 rue du Dr ROUX, 75015, Paris, France.
micheline.guillotte-blisnick@pasteur.fr.
(3)Institut Pasteur, Plate-forme de Production de Protéines recombinantes et
d'Anticorps (PF5), 25-28 rue du Dr ROUX, 75015, Paris, France. natofar@gmail.fr.
(4)Institut Pasteur, Unité d'Immunologie Structurale, 25-28 rue du Dr ROUX,
75015, Paris, France. alexandre.juillerat@cellectis.com.
(5)CNRS URA 2185, 25-28 rue du Dr ROUX, 75015, Paris, France.
alexandre.juillerat@cellectis.com.
(6)Institut Pasteur, Unité d'Immunologie Moléculaire des Parasites, 25-28 rue du 
Dr ROUX, 75015, Paris, France. audrey.hessel@ibs.fr.
(7)Institut Pasteur, Unité d'Immunologie Structurale, 25-28 rue du Dr ROUX,
75015, Paris, France. audrey.hessel@ibs.fr.
(8)Institut Pasteur, Plate-forme de Production de Protéines recombinantes et
d'Anticorps (PF5), 25-28 rue du Dr ROUX, 75015, Paris, France.
francoise.marchand@pasteur.fr.
(9)Institut Pasteur, Unité d'Immunologie Structurale, 25-28 rue du Dr ROUX,
75015, Paris, France. anita.bentley@orange.fr.
(10)CNRS URA 2185, 25-28 rue du Dr ROUX, 75015, Paris, France.
anita.bentley@orange.fr.
(11)Institut Pasteur, Unité d'Immunologie Structurale, 25-28 rue du Dr ROUX,
75015, Paris, France. graham.bentley@pasteur.fr.
(12)CNRS URA 2185, 25-28 rue du Dr ROUX, 75015, Paris, France.
graham.bentley@pasteur.fr.
(13)Institut Pasteur, Unité d'Immunologie Moléculaire des Parasites, 25-28 rue du
Dr ROUX, 75015, Paris, France. ines@pasteur.mg.
(14)URA CNRS 2581, 25-28 rue du Dr ROUX, 75015, Paris, France. ines@pasteur.mg.
(15)Institut Pasteur de Madagascar, Unité d'Immunologie des Maladies
Infectieuses, BP 1274, Antananarivo 101, Madagascar. ines@pasteur.mg.
(16)Institut Pasteur, Unité d'Immunologie Moléculaire des Parasites, 25-28 rue du
Dr ROUX, 75015, Paris, France. odile.puijalon@pasteur.fr.
(17)URA CNRS 2581, 25-28 rue du Dr ROUX, 75015, Paris, France.
odile.puijalon@pasteur.fr.

BACKGROUND: Rosetting, namely the capacity of the Plasmodium falciparum-infected 
red blood cells to bind uninfected RBCs, is commonly observed in African children
with severe malaria. Rosetting results from specific interactions between a
subset of variant P. falciparum erythrocyte membrane protein 1 (PfEMP1) adhesins 
encoded by var genes, serum components and RBC receptors. Rosette formation is a 
redundant phenotype, as there exists more than one var gene encoding a
rosette-mediating PfEMP1 in each genome and hence a diverse array of underlying
interactions. Moreover, field diversity creates a large panel of
rosetting-associated serotypes and studies with human immune sera indicate that
surface-reacting antibodies are essentially variant-specific. To gain better
insight into the interactions involved in rosetting and map surface epitopes, a
panel of monoclonal antibodies (mAbs) was investigated.
METHODS: Monoclonal antibodies were isolated from mice immunized with PfEMP1-VarO
recombinant domains. They were characterized using ELISA and reactivity with the 
native PfEMP1-VarO adhesin on immunoblots of reduced and unreduced extracts, as
well as SDS-extracts of Palo Alto 89F5 VarO schizonts. Functionality was assessed
using inhibition of Palo Alto 89F5 VarO rosette formation and disruption of Palo 
Alto 89F5 VarO rosettes. Competition ELISAs were performed with biotinylated
antibodies against DBL1 to identify reactivity groups. Specificity of mAbs
reacting with the DBL1 adhesion domain was explored using recombinant proteins
carrying mutations abolishing RBC binding or binding to heparin, a potent
inhibitor of rosette formation.
RESULTS: Domain-specific, surface-reacting mAbs were obtained for four individual
domains (DBL1, CIDR1, DBL2, DBL4). Monoclonal antibodies reacting with DBL1
potently inhibited the formation of rosettes and disrupted Palo Alto 89F5 VarO
rosettes. Most surface-reactive mAbs and all mAbs interfering with rosetting
reacted on parasite immunoblots with disulfide bond-dependent PfEMP1 epitopes.
Based on competition ELISA and binding to mutant DBL1 domains, two distinct
binding sites for rosette-disrupting mAbs were identified in close proximity to
the RBC-binding site.
CONCLUSIONS: Rosette-inhibitory antibodies bind to conformation-dependent
epitopes located close to the RBC-binding site and distant from the
heparin-binding site. These results provide novel clues for a rational
intervention strategy that targets rosetting.

DOI: 10.1186/s12936-015-1016-5 
PMCID: PMC4715314
PMID: 26772184  [Indexed for MEDLINE]

